Design, Synthesis and Structure-Activity Relationships of Phenylalanine-Containing Peptidomimetics as Novel HIV-1 Capsid Binders Based on Ugi Four-Component Reaction

As a key structural protein, HIV capsid (CA) protein plays multiple roles in the HIV life cycle, and is considered a promising target for anti-HIV treatment. Based on the structural information of CA modulator PF-74 bound to HIV-1 CA hexamer, 18 novel phenylalanine derivatives were synthesized via the Ugi four-component reaction. In vitro anti-HIV activity assays showed that most compounds exhibited low-micromolar-inhibitory potency against HIV. Among them, compound I-19 exhibited the best anti-HIV-1 activity (EC50 = 2.53 +/- 0.84 mu M, CC50 = 107.61 +/- 27.43 mu M). In addition, I-14 displayed excellent HIV-2 inhibitory activity (EC50 = 2.30 +/- 0.11 mu M, CC50 > 189.32 mu M) with relatively low cytotoxicity, being more potent than that of the approved drug nevirapine (EC50 > 15.02 mu M, CC50 > 15.2 mu M). Additionally, surface plasmon resonance (SPR) binding assays demonstrated direct binding to the HIV CA protein. Moreover, molecular docking and molecular dynamics simulations provided additional information on the binding mode of I-19 to HIV-1 CA. In summary, we further explored the structure-activity relationships (SARs) and selectivity of anti-HIV-1/HIV-2 of PF-74 derivatives, which is conducive to discovering efficient anti-HIV drugs.

Automated summary

This study investigated the inhibitory activity of phenylalanine derivatives against HIV. The results showed that compound I-19 exhibited the best anti-HIV-1 activity, while compound I-14 displayed excellent HIV-2 inhibitory activity. Additionally, the binding ability of these compounds to HIV was confirmed. These findings contribute to the discovery of effective anti-HIV drugs.